When former patients were reidentified after a median follow-up of 70 months ( range = 0-136 ) , the actuarial 10-year disease-free survival rate in the SeG was 80.1 % compared to 83.2 % in the CG ( P = .65 ) , and the actuarial 10-year overall survival rate of patients in the SeG was 55.3 % compared to 42.7 % in the CG ( P = .09 ) .